Pro-opiomelanocortin messenger RNA levels increase in the fetal sheep pituitary during late gestation

Combined Antioxidant and Glucocorticoid Therapy for Safer Treatment of Preterm Birth

Ante- and postnatal glucocorticoid therapy reduces morbidity and mortality in the preterm infant, and it is therefore one of the best examples of the successful translation of basic experimental science into human clinical practice. However, accruing evidence derived from human clinical studies and from experimental studies in animal models raise serious concerns about potential long-term adverse effects of treatment on growth and neurological and cardiovascular function in the offspring. This review explores whether combined antioxidant and glucocorticoid therapy may be safer than glucocorticoid therapy alone for the treatment of preterm birth.

Effects of maternal dexamethasone treatment in early pregnancy on pituitary-adrenal axis in fetal sheep

Fetal exposure to elevated levels of bioactive glucocorticoids early in gestation, as in suspected cases of congenital adrenal hyperplasia, may result in adverse neurological events. Fetal hypothalamic-pituitary-adrenal development and function may be involved. We investigated immediate and long-term effects of maternal dexamethasone (DEX) administration early in pregnancy on fetal growth and pituitary-adrenal activity in sheep. Pregnant ewes carrying singleton fetuses (total n = 119) were randomized to control (2 ml saline/ewe) or DEX-treated groups (im injections of 0.14 mg/kg ewe weight . 12 h) at 40-41 d gestation (dG). At 50, 100, 125, and 140 dG, fetal plasma and tissues were collected. DEX-exposed fetuses were lighter than controls at 100 dG (P < 0.05) but not at any other times. Fetal plasma ACTH levels and pituitary POMC and PC-1 mRNA levels were similar between groups. Fetal plasma cortisol levels were significantly reduced after DEX exposure in both male and female fetuses at 50 dG (P < 0.05), were similar at 100 and 125 dG, but were significantly higher than controls at 140 dG. At 140 dG, there was increased adrenal P450C(17) and 3beta-HSD mRNA in female fetuses and reduced expression of ACTH-R mRNA in males. Fetal hepatic CBG mRNA levels mimicked plasma cortisol patterns. DEX exposure reduced CBG only in males at 50 dG (P < 0.05). Placental mRNA levels of 11beta-HSD2 were increased after DEX in males (P < 0.05). Therefore, in sheep, early DEX may alter the developmental trajectory of the fetal hypothalamic-pituitary-adrenal axis, directly increasing fetal adrenal activation but not anterior pituitary function. In females, this effect may be attributed, in part, to increased fetal adrenal steroidogenic activity.

Neuroendocrine regulation of gonadotropins in the male and the female

For the past decade, neuroendocrinology, in general, and neuroendocrine regulation of reproduction, in particular, were strongly dominated by molecular genetics and molecular endocrinology. In very recent years, however, neuroendocrinology is taking back its place. Beyond doubt GnRH is the neuroendocrine signal for ovulation. But there are still many unexplored pathways within the 'black box' triggering and regulating this signal. Neuroendocrine control of reproduction starts very early in life, well before birth. Hypophyseal gonadotropin secretion is under hypothalamic control at around mid-gestation in the fetal sheep and the fetal pig. These two species could be considered as best-studied farm animals considering neuroendocrinology. This minireview thus will give in the first part a short survey of developmental processes of some of the neuroendocrine systems in the pig and sheep. In the second part, the opioidergic and catecholaminergic control of gonadotropins in adults will be briefly discussed. The last part will focus on the new less known pathways mediating effects on hormones which regulate the reproductive functions.

Functional heterogeneity of corticotrophs in the anterior pituitary of the sheep fetus

1. Parturition in the sheep is dependent on prepartum stimulation of the hypothalamo-pituitary-adrenal axis and an increase in fetal plasma cortisol concentration. We have investigated whether there are changes in the functional characteristics of the corticotrophic cells in the week before delivery or in response to an increase in circulating cortisol. 2. Fetal sheep were infused with cortisol (2-3 mg 24 h-1 i.v.; n = 11), or saline (4.4 ml 24 h-1 i.v.; n = 10) between 109 and 116 days gestation and pituitary glands were collected from these two groups, and from a late gestational group (140-145 days gestation; n = 10) for cell culture. Cells in half the wells from each pituitary were treated with cytotoxin (Cx; a cytotoxic analogue of corticotrophin releasing hormone (CRH)) to eliminate CRH target cells before exposure to ovine (o)CRH (10-8 M), arginine vasopressin (AVP; 10-7 M) or oCRH + AVP. 3. We have demonstrated that around 70 % of adrenocorticotrophic hormone (ACTH) in the fetal anterior pituitary is stored within corticotrophs which are CRH responsive. Cortisol acts to inhibit ACTH synthesis in corticotrophic cells which are CRH responsive, whereas AVP-responsive cells in the fetal pituitary are relatively resistant to cortisol. 4. We propose that the stimulatory influence of the fetal hypothalamus must counteract the negative feedback effect of cortisol in the CRH-responsive cells to stimulate the increase in pituitary ACTH output which occurs before delivery.

Fetal sheep pituitary proopiomelanocortin in late gestation: effect of bilateral lesions of the paraventricular nucleus on regional and cellular messenger ribonucleic acid levels

Previous experiments have clearly indicated that the successful completion of ovine gestation is dependent upon fetal adrenocortical maturation and the associated preterm rise in fetal plasma cortisol. The purposes of this study were to: 1) examine pituitary POMC messenger RNA (mRNA) levels during normal fetal development; and 2) examine the effects of bilateral lesion of the fetal paraventricular nucleus (PVN) on levels and spatial distribution of pituitary POMC mRNA. Pituitary glands were collected from intact fetal sheep of four gestational ages [100-107 days gestational age (dga), n = 8; 117-121 dga, n = 9; 126-130 dga, n = 9; 144-147 dga, n = 8]. Lesions of the PVN (PVN Lx; n = 4) or sham lesions (Sham; n = 5) were performed at 118-122 dga. Pituitary glands from PVN Lx and Sham fetuses were collected at 139-142 dga (term approximately 147 dga). POMC mRNA levels were determined by in situ hybridization. POMC transcript levels were determined by both regional analysis (20x magnification) and analysis of individual corticotropes (400x magnification). There was no difference among gestational age groups in superior anterior pituitary (AP) POMC mRNA levels determined by regional or cellular analysis. POMC mRNA levels were significantly greater in the inferior AP at 144-147 dga, compared with other gestational ages, using regional analysis (P = 0.003) or analysis of individual corticotropes (P < 0.01). POMC mRNA levels in the neurointermediate lobe in 126- to 130-dga fetuses were significantly greater than those in younger fetuses (P = 0.005) but not those in 144- to 147-dga fetuses. There was no difference in POMC mRNA levels in the superior AP between PVN Lx and Sham, using regional analysis or analysis of individual corticotropes. In the inferior AP, there was a significant decrease in POMC mRNA levels in PVN Lx, compared with Sham, using both regional analysis (P < 0.01) and cellular analysis (P < 0.01). There was no difference in POMC mRNA levels in the neurointermediate lobe as the result of bilateral PVN Lx. Our findings support that basal AP POMC mRNA levels are heterogenously distributed in the ovine fetal AP, with POMC mRNA levels in the inferior AP being significantly greater than in superior AP, by 144-147 dga. We further found that the higher POMC mRNA levels in the inferior AP reflect significantly higher corticotrope POMC transcripts and not simply a greater density of corticotropes in this AP region. The increase in POMC mRNA levels at 144-147 dga in the inferior AP seems unrelated to the onset of adrenocortical maturation (at approximately 125-130 dga). Finally, we report that increase in corticotrope POMC transcripts during late gestation in the inferior AP requires an intact PVN.

CRH and AVP-induced changes in synthesis and release of ACTH from the ovine fetal pituitary in vitro: negative influences of cortisol

During late gestation in sheep, fetal plasma adreno-corticotrophin (ACTH) and cortisol levels increase, and these are associated with increased pro-opiomelanocortin (POMC) mRNA levels in the anterior pituitary. Corticotrophin-releasing hormone (CRH) and vasopressin (AVP) are the primary hypophysiotrophic factors regulating ACTH secretion from the fetal sheep pituitary corticotroph, but previous reports with term fetal tissue have failed to show effects on levels of POMC mRNA. The objectives of the present study were to establish the effects of CRH and AVP on both synthesis and secretion of ACTH before term, and to determine how cortisol affects these responses. Fetal pituitaries were removed at d 138 of gestation (term approximately d 147), the anterior pituitary was separated, and the cells dispersed and placed in monolayer tissue culture. After 4 d, cells were treated for 18 h with several different concentrations (10(-6)-10(-9) M) and combinations of CRH, AVP, and cortisol. Following incubation, the medium was removed for ACTH analysis, and the cells fixed for POMC mRNA measurement and immunoreactive (ir)-ACTH localization. Separately, CRH and AVP significantly (p < 0.05) stimulated ACTH secretion in a dose-dependent manner. Simultaneous treatment of maximally stimulating levels of CRH and AVP augmented (p < 0.05) the output of ACTH. Cortisol did not affect basal (nonstimulated) ACTH output, but attenuated the neuropeptide-induced increases in ACTH secretion. This effect of cortisol was more pronounced in cells treated with CRH than in cells treated with AVP. POMC mRNA levels were increased by both CRH and AVP treatments in a dose-dependent manner, though there was no further increase in POMC mRNA when CRH and AVP were added together. Cortisol attenuated (p < 0.05) the neuropeptide-induced increases in POMC mRNA, though AVP-stimulated POMC mRNA levels were significantly higher than in cells treated with cortisol alone. Cortisol failed to alter non-stimulated POMC mRNA levels. We conclude that in late gestation: 1) Fetal pituitary corticotrophs respond to CRH and AVP by increasing POMC mRNA levels and ACTH secretion 2) AVP is more potent than CRH at the level of ACTH secretion, but not POMC transcription 3) Cortisol attenuates the synthetic and secretory responses to CRH and AVP, but has little effect in the non-stimulated state.

Placental restriction alters the functional development of the pituitary-adrenal axis in the sheep fetus during late gestation

We have experimentally restricted placental growth in the sheep to investigate the impact of reduced substrate delivery on fetal pituitary proopiomelanocortin (POMC) mRNA levels and on circulating ACTH 1-39, immunoreactive ACTH, and cortisol concentrations during late gestation. Endometrial caruncles were removed in nine ewes before mating to reduce the number of placentomes formed [placental restriction group (PR)]. Fetal arterial PO2 and O2 saturation were reduced in the PR group (2.0 +/- 0.1 kPa and 42.8 +/- 1.1%, n = 9) when compared with control fetuses (3.1 +/- 0.1 kPa and 66.4 +/- 0.9%, n = 10). The ratio of anterior pituitary POMC mRNA:18 S ribosomal RNA was also lower (p < 0.05) in the PR group (0.49 +/- 0.05) when compared with the control group (0.80 +/- 0.12) after 140 d of gestation. In contrast, plasma concentrations of ACTH 1-39 and immunoreactive ACTH were similar in the PR and control groups throughout late gestation. Plasma ACTH 1-39 concentrations increased (p < 0.006) between 128 and 134 d of gestation, in both the PR (122-128 d: 2.70 +/- 0.34 pmol/L: 134-141 d; 7.07 +/- 1.57 pmol/L) and control (122-128 d; 3.36 +/- 0.56 pmol/L: 134-141 d; 10.78 +/- 2.88 pmol/L) groups. Combined adrenal weight was higher (p < 0.005) in the PR group (130 +/- 10 mg/kg) compared with controls (80 +/- 1 mg/kg) at 140 d of gestation, and plasma cortisol concentrations were also higher (p < 0.02) in PR than control fetuses between 127 and 141 d of gestation. These changes imply that the fetal hypothalamopituitary-adrenal axis is operating at a new central set point in the growth-restricted fetus.

Regulation of the hypothalamo-pituitary-adrenocortical axis in fetal sheep

Development of the fetal hypothalamo-pituitary-adrenal (HPA) axis is required for normal fetal life and subsequent neonatal health. Activation of the fetal pituitary gland results in the synthesis and release of glucocorticoids from the adrenal cortex. Glucocorticoids promote maturation of several organ systems, are important in responses of the fetus to stress, and are involved in the initiation of parturition in several species. The expression of hypothalamic and pituitary genes associated with HPA function is apparent early in gestation in fetal sheep, although the endocrine changes associated with maturation and parturition do not occur until the last fifth of gestation. In this connection, the fetal HPA axis can be activated by treatment with hypophysiotrophic factors or moderate stress throughout gestation. This review focuses on the development of neuroendocrine mechanisms controlling HPA function during fetal life.

Corticosteroid-binding globulin (CBG) in fetal development

In fetal sheep the prepartum increase in plasma cortisol concentration is associated with an increase in high affinity corticosteroid binding activity in plasma. This appears to reflect an increase in corticosteroid-binding globulin (CBG) biosynthesis from the fetal liver, and evidence is presented that hepatic CBG gene expression is increased by exposure to glucocorticoids in the fetus. Immunoreactive CBG is found in other fetal tissues, and CBG mRNA is present in fetal pituitary. CBG reduces the ability of cortisol to exert negative feedback on basal or CRH-stimulated ACTH output by fetal sheep pituitary cells in culture. We suggest that CBG interacts with cortisol in a manner that maintains a low negative feedback on the pituitary, and perhaps hypothalamus. This constitutes a component of the cascade of events that is associated with hypothalamic-pituitary-adrenal activation in the late gestation fetus, and with the onset of parturition.

Foetal endocrine maturation

In domestic ruminants such as the sheep, birth is effected through sequential maturation of the foetal hypothalamic-pituitary-adrenal (HPA) axis, leading to the increased output of cortisol. Factors regulating foetal pituitary adrenocorticotrophin (ACTH) secretion have been delineated, and these include corticotrophin releasing hormone (CRH), arginine vasopressin, prostaglandin (PG) E2 and endogenous opioids. The pre-partum increase in foetal plasma ACTH is associated with a rise in pro-opiomelanocortin (POMC) mRNA in the foetal pars distalis, and with an altered pattern of POMC post-translational processing. Foetal adrenal activation results from an increase in ACTH receptors and enhanced coupling through the Gs protein to adenylate cyclase, and increased expression of key steroidogenic enzymes including P450c17. Cortisol modulates the mechanism by which ACTH activates foetal adrenal function, through specific glucocorticoid receptors (GR) in the foetal adrenal cortex. Although the numbers of GR change with gestation, the relative abundance of GR mRNA does not, pointing to post-translational regulatory mechanisms. Cortisol also stimulates an increase in the concentration of its own high affinity binding protein (corticosteroid binding globulin; CBG) in the foetal circulation, apparently by increasing CBG gene expression in the foetal liver, and by altering the extent of foetal CBG glycosylation in a manner that would be expected to decrease the metabolic clearance of this glycoprotein. Clear evidence for placental CRH and ACTH production is lacking in sheep, but PGE2, produced in increasing amounts by the placenta during late pregnancy, may augment the drive to HPA maturation. Aspects of the maturational pathway of cortisol biosynthesis have been described in other species, including the horse, and some comparison is made with the more detailed information currently available from species such as the sheep.